Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-134813
Filing Date
2026-03-31
Accepted
2026-03-31 16:49:08
Documents
70
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K inkt-20251231.htm   iXBRL 10-K 2366983
2 EX-21.1 inkt-ex21_1.htm EX-21.1 6989
3 EX-23.1 inkt-ex23_1.htm EX-23.1 3866
4 EX-31.1 inkt-ex31_1.htm EX-31.1 17298
5 EX-31.2 inkt-ex31_2.htm EX-31.2 17240
6 EX-32.1 inkt-ex32_1.htm EX-32.1 10201
7 EX-32.2 inkt-ex32_2.htm EX-32.2 10140
8 GRAPHIC img193888466_0.jpg GRAPHIC 129242
  Complete submission text file 0001193125-26-134813.txt   8312250

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inkt-20251231.xsd EX-101.SCH 1169381
74 EXTRACTED XBRL INSTANCE DOCUMENT inkt-20251231_htm.xml XML 1023210
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40908 | Film No.: 26822944
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)